Phase II Trial of RAD001 (Everolimus) in Previously Treated Small Cell Lung Cancer

Small Cell Lung Cancer Clinical Trial

Official title:

Phase II Trial of RAD001 (Everolimus) in Previously Treated Small Cell Lung Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00374140
• Other study ID #: 06-049
• Status: Completed
• Phase: Phase 2
• First received: September 6, 2006
• Last updated: September 18, 2017
• Start date: October 2006
• Est. completion date: June 2012

Study information

• Verified date: September 2017
• Source: University of Pittsburgh
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase II, two-stage, open-label, single-agent study of the experimental drug RAD001 (everolimus) in patients with previously treated small cell lung cancer. RAD001 will be administered orally at a dose of 10 mg daily.

Description:

This is a phase II, two-stage, open-label, single-agent study of the experimental drug RAD001 (everolimus) in patients with previously treated small cell lung cancer. Patients may have received up to 2 prior chemotherapy regimens for small cell lung carcinoma, but no prior therapy with an m-TOR inhibitor. RAD001 will be administered orally at a dose of 10 mg daily. A cycle will be defined as 3 weeks of study drug administration, and patients will have tumor measurements every 2 cycles. Study participation will continue until disease progression or intolerable toxicities. In addition, in patients who consent, archival tumor tissue (paraffin block from original biopsy) will be collected for research purposes.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: June 2012
• Est. primary completion date: December 2008
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Cytologically or histologically confirmed small cell carcinoma of the lung that has progressed post first-line therapy. Mixed small and non-small cell tumors are excluded.

2. Prior chemotherapy for small cell carcinoma. Up to 2 prior chemotherapy regimens for small cell lung carcinoma are allowed. No prior therapy with an m-TOR inhibitor (e.g. CCI-779).

3. Unidimensionally measurable disease (RECIST criteria). If the only site of measurable disease is in a previously irradiated area, the patient must have documented progression of disease in this area.

4. ECOG performance status 0-2.

5. A minimum of 4 weeks should elapse from prior chemotherapy. Patients must have fully recovered from the effects of any prior surgery or radiation therapy or other anticancer therapies, including immunotherapy and investigational agents.

6. No progressive brain metastases. Brain metastases should have been previously treated with surgery and/or radiation.

7. Patients with a prior malignancy should have at least 3 years of disease-free survival. Prior curatively treated squamous cell or basal carcinoma of the skin or in situ cervical cancer or other in situ malignancies are allowed.

8. No other coexisting medical condition that would preclude full compliance with the study.

9. Required laboratory values (obtained < 1 week prior to enrollment):

• ANC >/= 1500/mm³

• Platelets >/= 100,000/mm³

• AST and ALT = 3 x ULN (upper limits of normal). In patients with liver metastases AST and ALT should be < 5 x ULN.

• Total bilirubin up to 1.5 x ULN (upper limits of normal).

10. Age >/= 18 years and capacity to give informed consent.

11. Patients should be advised to discontinue drugs that interact with CYP3A4 (see list of examples in Table 3.1 of the full protocol), if medically safe.

12. All patients must have given signed, informed consent prior to registration on study.

Exclusion Criteria:

1. Prior treatment with any investigational agent within the preceding 4 weeks.

2. Other concurrent severe and/or uncontrolled medical disease which could compromise participation in the study (i.e., uncontrolled diabetes, uncontrolled hypertension, severe infection, severe malnutrition, unstable angina, or congestive heart failure - New York Heart Association Class III or IV, ventricular arrhythmias active ischemic heart disease, myocardial infarction within six months, chronic liver or renal disease, active upper GI tract ulceration).

3. A known history of HIV seropositivity.

4. Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of RAD001 (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection).

5. Patients with an active, bleeding diathesis or on anticoagulation (except low dose warfarin).

6. Pregnant and lactating women are excluded from the study because the agents used in this study may be teratogenic to a fetus and there is no information on the excretion of the agents or their metabolites into breast milk.

7. Women of childbearing potential and sexually active males must agree to use an accepted and effective method of contraception (hormonal or barrier methods, abstinence) prior to study entry and for the duration of the study.

8. Patients should not be on chronic systemic glucocorticoids or other immunosuppressant.

Related Conditions & MeSH terms

• Lung Neoplasms
• Small Cell Lung Cancer
• Small Cell Lung Carcinoma

Intervention

Drug:
• RAD001 (everolimus)
10 mg by mouth daily without interruption for 3-week cycles until disease progression or intolerable toxicities

Locations

Country	Name	City	State
United States	UPMC Cancer Center - Beaver	Beaver	Pennsylvania
United States	UPMC Cancer Center - Clairton	Clairton	Pennsylvania
United States	UPMC Cancer Center - Arnold Palmer Pavilion - Greensburg	Greensburg	Pennsylvania
United States	UPMC Cancer Center - Oakbrook Commons - Greensburg	Greensburg	Pennsylvania
United States	UPMC Cancer Center - Indiana	Indiana	Pennsylvania
United States	UPMC Cancer Center - John P. Murtha Pavilion - Johnstown	Johnstown	Pennsylvania
United States	UPMC Cancer Center - McKeesport	McKeesport	Pennsylvania
United States	UPMC Cancer Center - Monroeville	Monroeville	Pennsylvania
United States	UPMC Cancer Center - Sewickley Medical Oncology/Hematology Group	Moon	Pennsylvania
United States	UPMC Cancer Center - New Castle	New Castle	Pennsylvania
United States	University of Pittsburgh Cancer Institute - Hillman Cancer Center	Pittsburgh	Pennsylvania
United States	UPMC Cancer Center - Mercy	Pittsburgh	Pennsylvania
United States	UPMC Cancer Center - Passavant	Pittsburgh	Pennsylvania
United States	UPMC Cancer Center - St. Margaret's	Pittsburgh	Pennsylvania
United States	UPMC Cancer Center - Upper St. Clair	Pittsburgh	Pennsylvania
United States	UPMC Cancer Center - Teramana Cancer Center - Steubenville	Steubenville	Ohio
United States	UPMC Cancer Center - Uniontown	Uniontown	Pennsylvania
United States	UPMC Cancer Center - Washington	Washington	Pennsylvania
United States	UPMC Cancer Center - North Hills	Wexford	Pennsylvania

Sponsors (2)

Lead Sponsor	Collaborator
Ahmad Tarhini	Novartis Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Determine the Proportion of Previously Treated Small Cell Lung Cancer (SCLC) Patients Whose Disease Has Not Progressed Following 6-weeks (2 Cycles) of Treatment With RAD001.		Two cycles of treatment with RAD001 (~6 weeks)
Secondary	Overall Survival		From entry in trial to up to 60 months
Secondary	Progression-free Survival		From entry into trial to up to 60 months
Secondary	Objective Response Rate	Number of patients for which response to treatment was observed / total number of patients.	From beginning of treatment up to 60 months